Special Issue "Personalizing Medicine by Sex, Gender and Hormonal Status: Progress, Opportunities and Challenges"
Deadline for manuscript submissions: 30 January 2022.
Biological sex, gender, and gonadal hormone status have a substantial influence on the incidence, prevalence, presentation, treatment response, and outcome of diverse disorders and pathologies across all medical fields. Despite increasing recognition of the importance of these variables, demographic data collected from patients and participants in clinical trials do not routinely include information on gonadal hormone status (e.g., puberty, stage of menstrual cycle, menopause, or andropause). In this Special Issue, practitioners and investigators in diverse fields of medicine summarize their experience and outline opportunities and challenges in the use of sex, gender, and gonadal hormone status to personalize and improve the diagnosis and treatment of conditions including diabetes, breast cancer, epilepsy, schizophrenia, and brain injury.Prof. Anat Biegon
Prof. Dr. Mary V. Seeman
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- sex differences
- personalized medicine
- gonadal hormone modulation
- brain function
- ovarian/endometrial cancer
- drug addiction
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
1.Title:Sex-specific Effects of progesterone-induced ALLOPREGNANOLONE on Cognitive Performance in Cocaine use disorder: PRELIMINARY FINDINGS
Abstract: Background: Cognitive deficits have been observed in cocaine use disorder (CUD), and may play an important role in the progression, maintenance and risk for relapse of the disease. Therefore, interventions that improve cognition may prove clinically relevant in treatment seeking individuals with CUD. Here, we tested the role of the progesterone-derived neuroactive steroid allopregnanolone (ALLO) on cognitive performance in CUD men and CUD women who were all in the early follicular phase of their menstrual cycle. Methods: Twenty-seven individuals (8F/19M) with CUD received progesterone (400mg) vs. placebo for 7 days in early abstinence from cocaine. On day 5, levels of ALLO were measured and cognitive tasks completed. Participants were grouped by high or low ALLO and cognitive performance was compared between ALLO groups. Results: Women in the high ALLO group displayed significantly higher verbal fluency than low ALLO women, increased emotional reactivity in the Paced Auditory Serial Addition Test (PASAT), and reduced errors in Rey Auditory Verbal Learning Test (RAVLT) compared to women in the low ALLO group and men overall. Conclusions: Findings highlight the combined role of gender and gonadal hormones on salient relapse-related treatment targets in CUD populations. It further emphasizes the need for well-tailored, personalized medications in addiction.
2.Sex, gender and gonadal hormones differences in diabetes and obesity